The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The Gaucher Registry: Demographics and Disease Characteristics of 1698 Patients With Gaucher Disease
Abstract
BACKGROUND: The Gaucher Registry, the largest database of patients with Gaucher disease (GD) worldwide, was initiated to better delineate the progressive nature of the disorder and determine optimal therapy. This report describes the demographic and clinical characteristics of 1698 patients with GD before they received enzyme replacement therapy. METHODS: Physicians worldwide who treat patients with GD were invited to submit prospective and retrospective data for an ongoing registry, using standardized data collection forms, for central processing and review. RESULTS: Most patients were from the United States (45%) and Israel (17%), but patients are from 38 countries. Most (94%) had type 1 GD, fewer than 1% had type 2, and 5% had type 3. Mutant allele frequency data, available for 45% of patients, showed the most common alleles to be N370S (53%), L444P (18%), 84GG (7%), and IVS2+1 (2%). Twenty-five percent of L444P homozygotes (13 of 52 patients) had type 1 GD phenotype. Mean age at diagnosis in patients with the N370S/N370S genotype was 27.2 years (SD, 19.7 years); in L444P/L444P patients, 2. 3 years (SD, 3.2 years). Histories of bone pain and radiological bone disease were reported by 63% and 94% of patients, respectively; both were more likely in asplenic patients than in patients with spleens. Mean spleen and liver volumes were 19.8 and 2.0 multiples of normal, respectively. Anemia and thrombocytopenia were present in 64% and 56%, respectively. Thrombocytopenia was present in 13% of asplenic patients. CONCLUSIONS: The Gaucher Registry permits a comprehensive understanding of the clinical spectrum of GD because of the uniquely large sample size. The Registry will be useful in evaluating the effects of specific therapies in GD and the possible influences of environment, ethnicity, and genotype on the natural history of the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feinleib, M., & Zar, J. H. (1975) · Journal of the American Statistical Association · doi:10.2307/2285423 · Cited by 12,680
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher's disease
Brady, R. O., Kanfer, J. N., & Shapiro, D. (1965) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(65)90743-6 · Cited by 807
Grabowski, G. A., Barton, N. W., Pastores, G., Dambrosia, J. M., Banerjee, T. K., McKee, M. A., Parker, C., Schiffmann, R., Hill, S. C., & Brady, R. O. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00005 · Cited by 446
Self-citationGaucher Disease: Clinical, Laboratory, Radiologic, and Genetic Features of 53 Patients
Zimran, A., Kay, A., Gelbart, T., Garver, P., Thurston, D., Saven, A., & Beutler, E. (1992) · Medicine · doi:10.1097/00005792-199211000-00002 · Cited by 336
Self-citationPREDICTION OF SEVERITY OF GAUCHER'S DISEASE BY IDENTIFICATION OF MUTATIONS AT DNA LEVEL
Zimran, A., Gross, E., West, C., Sorge, J., Kubitz, M., & Beutler, E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90536-9 · Cited by 278
Self-citation3 Gaucher's disease: clinical features and natural history
Cox, T. M., & Schofield, J. P. (1997) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(97)80033-9 · Cited by 260
Enzyme therapy for Gaucher disease: the first 5 years
Grabowski, G. A., Leslie, N., & Wenstrup, R. (1998) · Blood Reviews · doi:10.1016/s0268-960x(98)90023-6 · Cited by 188
Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications.
Sibille, A., Eng, C. M., Kim, S. J., Pastores, G. M., & Grabowski, G. A. (1993) · PubMed · Cited by 157
Self-citationCharrow, J., Esplin, J. A., Gribble, T. J., Kaplan, P. B., Kolodny, E. H., Pastores, G. M., Scott, C. R., Wappner, R. S., Weinreb, N. J., & Wisch, J. S. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1754 · Cited by 155
Self-citation
Cited by
Registries for Evaluating Patient Outcomes: A User’s Guide
(2020) · doi:10.23970/ahrqepcregistries4 · Cited by 960
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020441 · Cited by 868
Weinreb, N. J., Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., et al. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01150-6 · Cited by 546
Self-citationTherapeutic goals in the treatment of Gaucher disease
Pastores, G. M., Weinreb, N. J., Aerts, H., Andria, G., Cox, T. M., Giralt, M., Grabowski, G. A., Mistry, P. K., & Tylki-Szymańska, A. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.009 · Cited by 422
Self-citationGenotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset
Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., Bar-Shira, A., & Orr-Urtreger, A. (2008) · Neurology · doi:10.1212/01.wnl.0000304039.11891.29 · Cited by 360
Gaucher disease: pathological mechanisms and modern management
Jmoudiak, M., & Futerman, A. H. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05351.x · Cited by 288
X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease
Dvir, H., Harel, M., McCarthy, A. A., Toker, L., Silman, I., Futerman, A. H., & Sussman, J. L. (2003) · EMBO reports · doi:10.1038/sj.embor.embor873 · Cited by 278
Skeletal aspects of Gaucher disease: a review
Wenstrup, R. J., Roca-Espiau, M., Weinreb, N. J., & Bembi, B. (2002) · The British Journal of Radiology · doi:10.1259/bjr.75.suppl_1.750002 · Cited by 273
Self-citationLysosomal storage disease overview
Sun, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.39 · Cited by 271
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
Gaucher disease: a comprehensive review
Rosenbloom, B. E., & Weinreb, N. J. (2013) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2013006060 · Cited by 181
Self-citationViable Mouse Models of Acid β-Glucosidase Deficiency
Xu, Y.-H., Quinn, B., Witte, D., & Grabowski, G. A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63566-3 · Cited by 170
Sun, Y., Quinn, B., Witte, D. P., & Grabowski, G. A. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500202-jlr200 · Cited by 72
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Tran, M. L., Génisson, Y., Ballereau, S., & Dehoux, C. (2020) · Molecules · doi:10.3390/molecules25143145 · Cited by 63
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease
Schiffer, V., Santiago-Mujika, E., Flunkert, S., Schmidt, S., Farcher, M., Loeffler, T., Schilcher, I., Posch, M., Neddens, J., Sun, Y., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227077 · Cited by 11
Metadata
- Authors
- Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., Weinreb, N. J., & Zimran, A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-10-09
- Volume
- 160
- Issue
- 18
- Pages
- 2835
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2161236662
- Cited by
- 574
- References
- 18
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.